GSK has announced a three-year cost-saving plan aimed at freeing up more money for its late-stage research and development programs. The strategy points to a stronger focus on pipeline assets that are further advanced and potentially closer to major regulatory and commercial milestones.
Alongside the spending shift, the company also plans to move its research headquarters. GSK presented the relocation as part of the broader overhaul, linking the site move with its effort to reshape how research resources are deployed.
CEO Luke Miels has not publicly detailed how far the changes will go, leaving the scale of the cost reductions unclear for now. That limited disclosure means questions remain around which parts of the organization may be affected as the plan unfolds over the next three years.
Taken together, the changes signal a more targeted R&D approach at GSK, with greater emphasis on funding later-stage programs while trimming costs elsewhere. More specifics on the savings, the headquarters transition and the impact on the company’s research setup are likely to draw close attention.
